Paris P, et al. - Researchers evaluated the relative value of currently available biomarkers to predict prostate cancer pathology outcomes when examined together in the same patients. Men with low-risk cancers (biopsy Gleason score ≤3+3, PSA ≤10ng/ml, and clinical stage ≤T2) who had immediate prostatectomy were included. Overall, 381 cases from UCSF and 279 cases from UW were used to obtain prostate tissue and pre-surgical plasma samples. TGFb1 and IL6SR were analyzed in plasma samples. For the GEMCaP copy number variation score and the cell cycle progression (CCP) score, DNA and RNA (extracted from prostate tissue) were analyzed. In univariate analysis, a direct association of both CCP and GEMCaP with minor upgrading/upstaging was evident. Among men with clinically low-risk prostate cancer undergoing prostatectomy, adverse pathology was significantly and independently predicted by biomarker signatures based on analysis of DNA and RNA.